DMAC
Price
$6.47
Change
-$0.00 (-0.00%)
Updated
Sep 11 closing price
Capitalization
348.9M
67 days until earnings call
Intraday BUY SELL Signals
SLDB
Price
$8.70
Change
-$0.37 (-4.08%)
Updated
Sep 11 closing price
Capitalization
932.32M
60 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

DMAC vs SLDB

DMAC vs SLDB Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
DMAC vs. SLDB commentary
Sep 12, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DMAC is a Hold and SLDB is a Hold.

Interact to see
Advertisement
SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SLDB($932M) has a higher market cap than DMAC($349M). SLDB YTD gains are higher at: 54.255 vs. DMAC (-18.719). DMAC has higher annual earnings (EBITDA): -39.17M vs. SLDB (-210.48M). SLDB has more cash in the bank: 378M vs. DMAC (43.5M). DMAC has less debt than SLDB: DMAC (185K) vs SLDB (20.2M). DMAC (0) and SLDB (0) have equivalent revenues.
DMACSLDBDMAC / SLDB
Capitalization349M932M37%
EBITDA-39.17M-210.48M19%
Gain YTD-18.71954.255-35%
P/E RatioN/AN/A-
Revenue00-
Total Cash43.5M378M12%
Total Debt185K20.2M1%
FUNDAMENTALS RATINGS
DMAC vs SLDB: Fundamental Ratings
DMAC
SLDB
OUTLOOK RATING
1..100
1079
VALUATION
overvalued / fair valued / undervalued
1..100
55
Fair valued
26
Undervalued
PROFIT vs RISK RATING
1..100
54100
SMR RATING
1..100
9998
PRICE GROWTH RATING
1..100
5738
P/E GROWTH RATING
1..100
1003
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SLDB's Valuation (26) in the Biotechnology industry is in the same range as DMAC (55). This means that SLDB’s stock grew similarly to DMAC’s over the last 12 months.

DMAC's Profit vs Risk Rating (54) in the Biotechnology industry is somewhat better than the same rating for SLDB (100). This means that DMAC’s stock grew somewhat faster than SLDB’s over the last 12 months.

SLDB's SMR Rating (98) in the Biotechnology industry is in the same range as DMAC (99). This means that SLDB’s stock grew similarly to DMAC’s over the last 12 months.

SLDB's Price Growth Rating (38) in the Biotechnology industry is in the same range as DMAC (57). This means that SLDB’s stock grew similarly to DMAC’s over the last 12 months.

SLDB's P/E Growth Rating (3) in the Biotechnology industry is significantly better than the same rating for DMAC (100). This means that SLDB’s stock grew significantly faster than DMAC’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
DMACSLDB
RSI
ODDS (%)
N/A
Bearish Trend 2 days ago
80%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
75%
Momentum
ODDS (%)
Bearish Trend 2 days ago
84%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bearish Trend 2 days ago
81%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
81%
Bearish Trend 2 days ago
86%
Advances
ODDS (%)
Bullish Trend 11 days ago
84%
Bullish Trend 10 days ago
80%
Declines
ODDS (%)
Bearish Trend 13 days ago
80%
Bearish Trend 2 days ago
89%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
86%
Bullish Trend 2 days ago
72%
Aroon
ODDS (%)
Bearish Trend 2 days ago
75%
Bullish Trend 2 days ago
87%
COMPARISON
Comparison
Sep 12, 2026
Stock price -- (DMAC: $6.47 vs. SLDB: $8.70)
Brand notoriety: DMAC and SLDB are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: DMAC: 80% vs. SLDB: 133%
Market capitalization -- DMAC: $348.9M vs. SLDB: $932.32M
DMAC [@Biotechnology] is valued at $348.9M. SLDB’s [@Biotechnology] market capitalization is $932.32M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $130.64B. The average market capitalization across the [@Biotechnology] industry is $2.24B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DMAC’s FA Score shows that 0 FA rating(s) are green while SLDB’s FA Score has 2 green FA rating(s).

  • DMAC’s FA Score: 0 green, 5 red.
  • SLDB’s FA Score: 2 green, 3 red.
According to our system of comparison, SLDB is a better buy in the long-term than DMAC.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DMAC’s TA Score shows that 3 TA indicator(s) are bullish while SLDB’s TA Score has 5 bullish TA indicator(s).

  • DMAC’s TA Score: 3 bullish, 6 bearish.
  • SLDB’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, SLDB is a better buy in the short-term than DMAC.

Price Growth

DMAC (@Biotechnology) experienced а -4.15% price change this week, while SLDB (@Biotechnology) price change was -15.12% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -6.09%. For the same industry, the average monthly price growth was -3.45%, and the average quarterly price growth was +2531.70%.

Reported Earning Dates

DMAC is expected to report earnings on Nov 18, 2026.

SLDB is expected to report earnings on Nov 11, 2026.

Industries' Descriptions

@Biotechnology (-6.09% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
DMAC
Daily Signal:
Gain/Loss:
SLDB
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
ALVGX11.780.08
+0.68%
American Century Focused Lg Cap Val R5
DFFVX43.820.27
+0.62%
DFA US Targeted Value I
AUENX19.11N/A
N/A
AQR Large Cap Defensive Style N
JERNX12.94N/A
N/A
Janus Henderson Global Real Estate N
DHIYX14.41N/A
N/A
Diamond Hill International Y

DMAC and

Correlation & Price change

A.I.dvisor indicates that over the last year, DMAC has been loosely correlated with VIR. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if DMAC jumps, then VIR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DMAC
1D Price
Change %
DMAC100%
N/A
VIR - DMAC
43%
Loosely correlated
+0.38%
ANNX - DMAC
42%
Loosely correlated
-4.83%
EDIT - DMAC
41%
Loosely correlated
+1.89%
SLDB - DMAC
39%
Loosely correlated
-4.08%
KRRO - DMAC
38%
Loosely correlated
+5.74%
More

SLDB and

Correlation & Price change

A.I.dvisor indicates that over the last year, SLDB has been loosely correlated with EDIT. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if SLDB jumps, then EDIT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SLDB
1D Price
Change %
SLDB100%
-4.08%
EDIT - SLDB
54%
Loosely correlated
+1.89%
FDMT - SLDB
51%
Loosely correlated
-2.37%
IMTX - SLDB
49%
Loosely correlated
+0.46%
RCKT - SLDB
49%
Loosely correlated
-3.74%
CRBU - SLDB
49%
Loosely correlated
-7.30%
More